Payment overview · 2025
General Payments
$112.98
6 reported records · 6 companies
Healthcare provider profile · identity verified
Tomas Vybiral, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · ELKIN, NC · NPI 1740285824
Verified facts
What the public records show
CMS Open Payments records show Tomas Vybiral, M.D. received $112.98 in general payments during 2025 across 6 reported records.
Abbott Laboratories accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 959 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $27.80 | 24.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.98 | 21.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.01 | 15.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.82 | 14.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.80 | 12.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$13.57 | 12.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $112.98 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $27.80 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.98 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| MYCARELINK Normalized: mycarelink |
Device | Medtronic, Inc. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 959 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
72 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
959 | 265 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 959 | 265 |
| Atorvastatin Calcium | Atorvastatin Calcium | 812 | 302 |
| Losartan Potassium | Losartan Potassium | 654 | 246 |
| Metoprolol Succinate | Metoprolol Succinate | 644 | 237 |
| Amlodipine Besylate | Amlodipine Besylate | 519 | 197 |
| Furosemide | Furosemide | 495 | 192 |
| Metoprolol Tartrate | Metoprolol Tartrate | 468 | 158 |
| Levothyroxine Sodium | Levothyroxine Sodium | 438 | 178 |
| Omeprazole | Omeprazole | 424 | 165 |
| Gabapentin | Gabapentin | 395 | 150 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 383 | 125 |
| Lisinopril | Lisinopril | 378 | 159 |
| Nitroglycerin | Nitroglycerin | 347 | 224 |
| Warfarin Sodium | Warfarin Sodium | 337 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 333 | 120 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 327 | 126 |
| Hydrochlorothiazide | Hydrochlorothiazide | 322 | 144 |
| Pantoprazole Sodium | Pantoprazole Sodium | 313 | 122 |
| Carvedilol | Carvedilol | 258 | 88 |
| Metformin Hcl | Metformin Hcl | 255 | 103 |
| Digoxin | Digoxin | 213 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 212 | 92 |
| Potassium Chloride | Potassium Chloride | 211 | 87 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 174 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 69 |
| Ezetimibe | Ezetimibe | 165 | 58 |
| Montelukast Sodium | Montelukast Sodium | 160 | 61 |
| Simvastatin | Simvastatin | 158 | 63 |
| Trazodone Hcl | Trazodone Hcl | 150 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 141 | 61 |
| Sertraline Hcl | Sertraline Hcl | 137 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 40 |
| Allopurinol | Allopurinol | 125 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 125 | 65 |
| Azithromycin | Azithromycin | 120 | 100 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 48 |
| Xarelto | Rivaroxaban | 110 | 32 |
| Spironolactone | Spironolactone | 101 | 41 |
| Bumetanide | Bumetanide | 95 | 34 |
| Meclizine Hcl | Meclizine Hcl | 88 | 41 |
| Ropinirole Hcl | Ropinirole Hcl | 88 | 36 |
| Glipizide | Glipizide | 85 | 37 |
| Ozempic | Semaglutide | 82 | 22 |
| Atenolol | Atenolol | 80 | 30 |
| Amiodarone Hcl | Amiodarone Hcl | 79 | 27 |
| Meloxicam | Meloxicam | 79 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 42 |
| Alendronate Sodium | Alendronate Sodium | 75 | 23 |
| Farxiga | Dapagliflozin Propanediol | 72 | 27 |
| Buspirone Hcl | Buspirone Hcl | 71 | 27 |
| Famotidine | Famotidine | 71 | 30 |
| Alprazolam | Alprazolam | 69 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 27 |
| Clonidine Hcl | Clonidine Hcl | 67 | 24 |
| Ondansetron Odt | Ondansetron | 64 | 30 |
| Levofloxacin | Levofloxacin | 63 | 54 |
| Repatha Sureclick | Evolocumab | 63 | 14 |
| Lovastatin | Lovastatin | 60 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 54 |
| Finasteride | Finasteride | 56 | 18 |
| Torsemide | Torsemide | 56 | 17 |
| Enalapril Maleate | Enalapril Maleate | 55 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 26 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 52 | 17 |
| Januvia | Sitagliptin Phosphate | 51 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 19 |
| Celecoxib | Celecoxib | 50 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 49 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 19 |
| Glipizide Er | Glipizide | 46 | 18 |
| Lorazepam | Lorazepam | 45 | 14 |
| Methylprednisolone | Methylprednisolone | 45 | 37 |
| Ranolazine Er | Ranolazine | 45 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 44 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 36 |
| Diltiazem Hcl | Diltiazem Hcl | 43 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 41 | 14 |
| Nystatin | Nystatin | 41 | 17 |
| Pregabalin | Pregabalin | 41 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 27 |
| Gemfibrozil | Gemfibrozil | 39 | 16 |
| Jardiance | Empagliflozin | 39 | 17 |
| Mirtazapine | Mirtazapine | 39 | 12 |
| Propranolol Hcl | Propranolol Hcl | 39 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 34 |
| Tramadol Hcl | Tramadol Hcl | 37 | 19 |
| Amoxicillin | Amoxicillin | 36 | 32 |
| Cilostazol | Cilostazol | 36 | 11 |
| Labetalol Hcl | Labetalol Hcl | 35 | 11 |
| Linzess | Linaclotide | 35 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 15 |
| Ibuprofen | Ibuprofen | 34 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | 13 |
| Baclofen | Baclofen | 32 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | 11 |
| Topiramate | Topiramate | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | 16 |
| Mounjaro | Tirzepatide | 31 | 11 |
| Praluent Pen | Alirocumab | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | 17 |
| Sucralfate | Sucralfate | 29 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | 13 |
| Donepezil Hcl | Donepezil Hcl | 28 | 11 |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | 13 |
| Colchicine | Colchicine | 27 | 19 |
| Propafenone Hcl | Propafenone Hcl | 27 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Prednisone | Prednisone | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 21 |
| Bupropion Xl | Bupropion Hcl | 23 | 11 |
| Glimepiride | Glimepiride | 23 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 13 |
| Valsartan | Valsartan | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Dofetilide | Dofetilide | 20 | suppressed |
| Lubiprostone | Lubiprostone | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Cartia Xt | Diltiazem Hcl | 17 | 12 |
| Estradiol | Estradiol | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 17 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 16 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $112.98 · 6 records | Abbott Laboratories | ELIQUIS, ETERNA, FARXIGA, MYCARELINK, REXULTI, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error